Do you need to test your new therapeutic drugs on a robust ex-vivo model ?


The relevance of some models can be sometimes questioned because the heterogeneity of tumors is not recreated. We have a solution!

Use our new ex-vivo histoculture protocols to explore directly on patient-derived models the effect of your new drugs : the perfect model for clinical simulation studies.

This approach allows to evaluate molecular signature, biomarker discovery and detect potential drug resistance mechanisms thanks to our SignArrays system, directly on the sliced patient-derived biopsies.



Yoon YS et al. Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer. Anticancer Res. 2017 Mar;37(3):1297-1303.

Delyon et al. Validation of a preclinical model for assessment of drug efficacy in melanoma. Oncotarget. 2016 Mar 15; 7(11): 13069–13081.

Jung PS et al. Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res. 2013 Mar;33(3):1029-1034.